PDCD1LG2 and cancer: Molecular profiling of individuals with immune checkpoint blockade (ICB) treatment for tumor mutation burden (TMB), individual gene mutation (PBRM1, BRCA2), T cell-inflamed gene expression profile (GEP), neoantigen load, cytolytic activity (CYT), and protein expression of checkpoints (CTLA-4, PD-L1, and PD-L2) revealed sex not only affected OS in different cancers but was also bias in the immune features across multiple cancer types [45].